Laboratory diagnosis of typhoid - CONTROL OF TYPHOID FEVER

Laboratory diagnosis of typhoid

(a) MICROBIOLOGICAL PROCEDURES: 


The definitive diagnosis of typhoid fever depends on the isolation of S. typhi from blood, bone marrow and stools. Blood culture is the mainstay of diagnosis of this disease.
Laboratory diagnosis of typhoid

(b) SEROLOGICAL PROCEDURE: 


Felix-Widal test measures agglutinating antibody levels against O and H antigens. Usually, O antibodies appear on day 6-8 and H antibodies on day 10-12 after the onset of disease. The test is usually performed on an acute serum (at first contact with the patient). The test has only moderate sensitivity and specificity. 
It can be negative in up to 30 per cent of culture - proven cases of typhoid fever. This may be because of prior antibiotic therapy that has blunted the antibody response. On the other hand, S. typhi shares O and H antigens with other salmonella serotypes and has cross- reacting epitopes with other Enterobacteriacae, and this can lead to false-positive results. Such results may also occur in other clinical conditions, e.g. malaria, typhus, bacteraemia caused by other organisms, and cirrhosis.

(c) NEW DIAGNOSTIC TESTS: 

Laboratory diagnosis of typhoid


The recent advances for quick and reliable diagnostic tests for typhoid fever as an alternative to the Widal test include the IDL Tubex® test marketed by a Swedish company, which reportedly can detect IgM09 antibodies from patient within a few minutes. Another rapid serological test, Typhidot, takes three hours to perform. 
It was developed in Malaysia for the detection of specific IgM and IgG antibodies against a 50 kD antigen of S. typhi. A newer version of the test, Typhidot-M®, was recently developed to detect specific IgM antibodies only. The dipstick test, developed in the Netherlands, is based on the binding of S. typhi specific IgM antibodies in samples to S. typhi lipopolysaccharide (LPS) antigen and the staining of bound antibodies by an anti-human IgM antibody conjugated to colloidal dye particles.

CONTROL OF TYPHOID FEVER


The control or elimination of typhoid fever is well within the scope of modern public health. This is an accomplished fact in many developed countries. There are generally three lines of defence against typhoid fever:
  • 1. control of reservoir
  • 2. control of sanitation, and
  • 3. immunization.
The weakest link in the chain of transmission is sanitation which is amenable to control.

1. Control of reservoir

Typhoid fever causes
The usual methods of control of reservoir are their Identification, isolation, treatment and disinfection.
a. CASES
  • (i) Early diagnosis: This is of vital importance as the early symptoms are non-specific. Culture of blood and stools are important investigations in the diagnosis of cases.
  • (ii) Notification: This should be done where such notification is mandatory.
  • (iii) Isolation: Since typhoid fever is infectious and has a prolonged course, the cases are better transferred to a hospital for proper treatment, as well as to prevent the spread of infection. As a rule, cases should be isolated till three bacteriologically negative stools and urine reports, are obtained on three separate days.
  • (iv) Treatment: The fluoroquinolones are widely regarded as the drug of choice for the treatment of typhoid fever. They are relatively inexpensive, well tolerated and more rapidly and reliably effective than the former first-line drugs, viz. chloramphenicol, ampicillin, amoxicillin and trimethoprim sulfamethoxazole (TMP-SMX). The antibiotics used in uncomplicated typhoid fever are as shown in Table 1. Patients seriously ill and profoundly toxic may be given an injection of hydrocortisone 100 mg daily for 3 to 4 days.
  • (v) Disinfection: Stools and urine are the sole sources of infection. They should be received in closed containers and disinfected with 5 per cent cresol for at least 2 hours. All soiled clothes and linen should be soaked in a solution of 2 per cent chlorine and steam-sterilized. Nurses and doctors should not forget to disinfect their hands.
  • (vi) Follow-up: Follow-up examination of stools and urine should be done for S. typhi 3 to 4 months after discharge of the patient, and again after 12 months to prevent the development of the carrier state. With early diagnosis and appropriate treatment, mortality has been reduced to about 1 per cent as compared to about 30 per cent in untreated cases.

(d) CARRIERS

Laboratory diagnosis of typhoid - CONTROL OF TYPHOID FEVER
Since carriers are the ultimate source of typhoid fever, their identification and treatment is one of the most radical ways of controlling typhoid fever. The measures recommended are:
  • (i) Identification: Carriers are identified by cultural and serological examinations. Duodenal drainage establishes the presence of salmonella in the biliary tract in carriers. The Vi antibodies are present in about 80 per cent of chronic carriers.
  • (ii) Treatment: The carrier should be given an intensive course of ampicillin or amoxycillin (4-6 g a day) together with Probenecid (2 g/day) for 6 weeks. These drugs are concentrated in the bile and may achieve eradication of the carrier state in about 70 per cent of carriers. Chloromycetin is considered worthless for cleating the carrier state.
  • (iii) Surgery: Cholecystectomy with concomitant ampicillin therapy has been regarded as the most successful approach to the treatment of carriers. Cure rate may be as high as 80 per cent. Urinary carriers are easy to treat, but refractory cases may need nephrectomy when one kidney is damaged and the other healthy.
  • (iv) Surveillance: The carriers should be kept under surveillance. They should be prevented from handling food, milk or water for others.
  • (v) Health education: Health education regarding washing of hands with soap, after defecation or urination, and before preparing food is an essential element. In short, the management of carriers continues to be an unsolved problem. This is the crux of the problem, in the elimination of typhoid fever.

2. Control of sanitation


Protection and purification of drinking water supplies, improvement of basic sanitation, and promotion of food hygiene are essential measures to interrupt transmission of typhoid fever. For instance, typhoid fever is never a major problem where there is a clean domestic water supply. Sanitary measures, not followed by health education may produce only temporary results. However, when sanitation is combined with health education, the effects tend to be cumulative, resulting in a steady reduction of typhoid morbidity.

3. Immunization


While ultimately, control of typhoid fever must take the form of improved sanitation and domestic and personal hygiene, these are long-term objectives in many developing countries. A complementary approach to prevention is immunization, which is the only specific preventive measure, likely to yield the highest benefit for the money spent Immunization against typhoid does not give 100 per cent protection, but it definitely lowers both the incidence and seriousness of the infection. It can be given at any age upwards of two years. It is recommended to:
  • (i) those living in endemic areas
  • (ii) household contacts
  • (iii) groups at risk of infection such as school children and hospital staff
  • (iv) travellers proceeding to endemic areas, and
  • (v) those attending melas and yatras

ANTI-TYPHOID VACCINES

ANTI-TYPHOID VACCINES
The old parenteral killed whole-cell vaccine was effective but produced strong side-effects Two safe and effective vaccines are now licensed and available One is based on defined subunit antigens, the other on whole-cell live attenuated bacteria

The Vi polysaccharide vaccine


This subunit vaccine was first licensed in the United States in 1994 It is composed of purified Vi capsular polysaccharide from the Ty2 S Typhi strain and elicits a T-cell independent IgG response that is not boosted by additional doses. The vaccine is administered subcutaneously or intramuscularly. The target value for each single human dose is about 25µg of the antigen. The vaccine is stable for 6 months at 37°C, and for 2 years at 22°C. The recommended storage temperature is 2-8°C. The Vi vaccine does not elicit adequate immune responses in children aged less than 2 years.

Vaccine Schedule


The vaccine is licensed for individuals aged ≥ 2 years. Only 1 dose is required, and the vaccine confers profection 7 days after injection. To maintain protection, revaccination is recommended every 3 years. The Vi polysaccharide vaccine can be co-administered with other vaccines relevant for international travellers, such as yellow fever and hepatitis A, and with vaccines of the routine childhood immunization programmes.

Safety


No serious adverse events and a minimum of local side. effects are associated with Vi vaccination. There are no contraindications to the use of this vaccine other than previous severe hypersensitivity reaction to vaccine components. Although the Vi polysaccharide vaccine is safe for HIV-infected individuals, the induction of protective antibodies is directly correlated to the levels of CD4 positive T-cells.

The Ty21a vaccine


This vaccine, which was first licensed in Europe in 1983 and in the USA in 1989, is an orally administered, live- attenuated Ty2 strain of S. Typhi in which multiple genes, including the genes responsible for the production of Vi, have been mutated chemically. The lyophilized vaccine is available as enteric coated capsules. Protection is markedly influenced by the number of doses and their spacing. There are currently no field trials to document the efficacy of Ty2la vaccine in children aged years. Ty21a requires storage at 2-8°C, it retains potency for approximately 14 days at 25°C.

Schedule


The capsules are licensed for use in individuals aged ≥ 5 years. The vaccine is administered every other day; on 1, 3, and 5th day, a 3-dose regimen is recommended. With the 3-dose regimen, protective immunity is achieved 7 days after the last dose. The recommendation is to repeat this series every 3 years for people living in endemic areas, and every year for individuals travelling; from non-endemic to endemic countries. The Ty2la vaccine may be given simultaneously with other vaccines, including live vaccines against polio, cholera, and yellow fever, or the measles. mumps and rubella (MMR) combination.

Safety and precautions


Proguanil and antibacterial drugs should be stopped from 3 days before until 3 days after giving Ty21a, as such drugs may harm live bacterial vaccines. The vaccine is unlikely to be efficacious if administrated at the time of ongoing diarrhoea. It is not known whether this live attenuated vaccine may cause foetal harm when administered to pregnant women. Ty21a can be administered to HIV-positive, asymptomatic individuals as long as the T-cell count (CD4) is >200/mm3.
Ty2la is remarkably well tolerated and has low rates of adverse events. The vaccine is not recommended in congenital or acquired immunodeficiency including treatment with Immuno-suppressive and antimitotic drugs, acute febrile illness and acute intestinal infection.

এই পোস্টটি পরিচিতদের সাথে শেয়ার করুন

পূর্বের পোস্ট দেখুন পরবর্তী পোস্ট দেখুন
এই পোস্টে এখনো কেউ মন্তব্য করে নি
মন্তব্য করতে এখানে ক্লিক করুন

নীতিমালা মেনে কমেন্ট করুন। প্রতিটি কমেন্ট রিভিউ করা হয়।

comment url